Patient and treatment characteristics
| Characteristics . | Entire cohort (N = 1885) . | Autologous HCT (N = 1079) . | Allogeneic HCT (N = 806) . | P* . |
|---|---|---|---|---|
| Sex | ||||
| Female, no. (%) | 1087 (57.7) | 622 (57.6) | 465 (57.7) | .95 |
| Ethnicity/race, no. (%) | ||||
| Non-Hispanic white | 1186 (62.9) | 739 (68.5) | 447 (55.5) | < .01 |
| Hispanic | 456 (24.2) | 212 (19.6) | 244 (30.3) | |
| Other | 243 (12.9) | 128 (11.9) | 115 (14.2) | |
| Age at HCT, y | ||||
| Median (range) | 44.4 (0.6-78.9) | 49.9 (11.6-78.9) | 37.4 (0.6-74.9) | < .01 |
| No. (%) < 35 | 575 (30.5) | 212 (19.6) | 363 (45.0) | < .01 |
| 35-50 | 644 (34.2) | 334 (31.0) | 310 (38.5) | |
| > 50 | 666 (35.3) | 533 (49.4) | 133 (16.5) | |
| Median follow-up after HCT, y (range) | ||||
| Entire cohort | 5.9 (1.0-14.0) | 5.6 (1-13.9) | 6.2 (1-14.0) | < .01 |
| Alive at censor date† | 7.0 (1.2-14.0) | 6.6 (1.2-13.9) | 7.1 (1.5-14.0) | |
| Diagnosis, N (%) | ||||
| Lymphoma | 727 (38.6) | 643 (59.6) | 84 (10.4) | < .01 |
| Acute leukemia | 482 (25.6) | 128 (11.9) | 354 (43.9) | |
| Multiple myeloma | 290 (15.4) | 290 (26.9) | ||
| Chronic leukemia | 240 (12.7) | 240 (29.8) | ||
| Other | 146 (7.7) | 18 (1.7) | 128 (15.9) | |
| Pre-HCT therapy | ||||
| Anthracycline dose, median (range)‡ | 180 (0-600) | 250 (0-650) | 80 (0-640) | < .01 |
| Chest radiation, no. (%) | 100 (5.3) | 86 (8.0) | 14 (1.7) | < .01 |
| Conditioning regimen, no. (%) | ||||
| Chemotherapy | 891 (47.3) | 598 (55.4) | 293 (36.4) | < .01 |
| Chemotherapy + TBI | 994 (52.7) | 481 (44.6) | 513 (63.6) | |
| BMI at HCT | ||||
| < 30 kg/m2 | 1425 (75.5) | 767 (71.1) | 656 (81.4) | < .01 |
| ≥ 30 kg/m2 | 462 (24.5) | 312 (28.9) | 150 (18.6) | |
| Graft source | ||||
| Peripheral blood stem cells | 1437 (76.2) | 1068 (99.0) | 369 (45.8) | < .01 |
| Bone marrow | 423 (22.4) | 4 (0.4) | 420 (52.0) | |
| Peripheral blood stem cells + bone marrow | 11 (0.6) | 7 (0.6) | 4 (0.5) | |
| Cord blood | 14 (0.8) | 13 (1.6) | ||
| Donor source | ||||
| Related | 561 (69.9) | |||
| Unrelated | 247 (30.1) | |||
| aGVHD, no. (%) | ||||
| Grade I or none | 516 (64.0) | |||
| Grade II-IV | 290 (36.0) | |||
| Chronic GVHD, no. (%) | ||||
| None | 268 (33.2) | |||
| Limited | 297 (36.8) | |||
| Extensive | 241 (29.9) |
| Characteristics . | Entire cohort (N = 1885) . | Autologous HCT (N = 1079) . | Allogeneic HCT (N = 806) . | P* . |
|---|---|---|---|---|
| Sex | ||||
| Female, no. (%) | 1087 (57.7) | 622 (57.6) | 465 (57.7) | .95 |
| Ethnicity/race, no. (%) | ||||
| Non-Hispanic white | 1186 (62.9) | 739 (68.5) | 447 (55.5) | < .01 |
| Hispanic | 456 (24.2) | 212 (19.6) | 244 (30.3) | |
| Other | 243 (12.9) | 128 (11.9) | 115 (14.2) | |
| Age at HCT, y | ||||
| Median (range) | 44.4 (0.6-78.9) | 49.9 (11.6-78.9) | 37.4 (0.6-74.9) | < .01 |
| No. (%) < 35 | 575 (30.5) | 212 (19.6) | 363 (45.0) | < .01 |
| 35-50 | 644 (34.2) | 334 (31.0) | 310 (38.5) | |
| > 50 | 666 (35.3) | 533 (49.4) | 133 (16.5) | |
| Median follow-up after HCT, y (range) | ||||
| Entire cohort | 5.9 (1.0-14.0) | 5.6 (1-13.9) | 6.2 (1-14.0) | < .01 |
| Alive at censor date† | 7.0 (1.2-14.0) | 6.6 (1.2-13.9) | 7.1 (1.5-14.0) | |
| Diagnosis, N (%) | ||||
| Lymphoma | 727 (38.6) | 643 (59.6) | 84 (10.4) | < .01 |
| Acute leukemia | 482 (25.6) | 128 (11.9) | 354 (43.9) | |
| Multiple myeloma | 290 (15.4) | 290 (26.9) | ||
| Chronic leukemia | 240 (12.7) | 240 (29.8) | ||
| Other | 146 (7.7) | 18 (1.7) | 128 (15.9) | |
| Pre-HCT therapy | ||||
| Anthracycline dose, median (range)‡ | 180 (0-600) | 250 (0-650) | 80 (0-640) | < .01 |
| Chest radiation, no. (%) | 100 (5.3) | 86 (8.0) | 14 (1.7) | < .01 |
| Conditioning regimen, no. (%) | ||||
| Chemotherapy | 891 (47.3) | 598 (55.4) | 293 (36.4) | < .01 |
| Chemotherapy + TBI | 994 (52.7) | 481 (44.6) | 513 (63.6) | |
| BMI at HCT | ||||
| < 30 kg/m2 | 1425 (75.5) | 767 (71.1) | 656 (81.4) | < .01 |
| ≥ 30 kg/m2 | 462 (24.5) | 312 (28.9) | 150 (18.6) | |
| Graft source | ||||
| Peripheral blood stem cells | 1437 (76.2) | 1068 (99.0) | 369 (45.8) | < .01 |
| Bone marrow | 423 (22.4) | 4 (0.4) | 420 (52.0) | |
| Peripheral blood stem cells + bone marrow | 11 (0.6) | 7 (0.6) | 4 (0.5) | |
| Cord blood | 14 (0.8) | 13 (1.6) | ||
| Donor source | ||||
| Related | 561 (69.9) | |||
| Unrelated | 247 (30.1) | |||
| aGVHD, no. (%) | ||||
| Grade I or none | 516 (64.0) | |||
| Grade II-IV | 290 (36.0) | |||
| Chronic GVHD, no. (%) | ||||
| None | 268 (33.2) | |||
| Limited | 297 (36.8) | |||
| Extensive | 241 (29.9) |